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Dementia has an estimated global prevalence of 35 million individuals 
(Alzheimer’s Disease International, 2009). In the UK 570,000 people live with 
dementia - a figure which will double over the next 30 years, reflecting global 
predictions (Alzheimer’s Disease International, 2009; DoH, 2009a). People 
with dementia are commonly prescribed complex medication regimens, 
containing both physical and psychotropic medication (Schubert et al, 2006). 
 
Medication related adverse events due to poor medication management are 
associated with significant morbidity and admission to secondary care 
(Pirmohamed et al, 2004). Medication management is the entire way in which 
medicines are selected, procured, delivered, prescribed, administered and 
reviewed to optimise the contribution that they make to producing informed 
and desired outcomes of patient care (Audit Commission, 2001). The 
importance of safe and effective medication management for people with 
dementia is recognised nationally in the UK, by both the National Dementia 
Strategy (DoH, 2010) and NICE guidance (National Collaborating Centre for 
Mental Health, 2007), and internationally (Ministry of Health Services, 2007; 
Agency for Healthcare Research and Quality, 2009; see table 1 for a 
summary of the key factors). However, medication management care 
pathways in dementia are often complex. In addition, there is an inherent 
tension between ensuring that the symptoms of dementia are treated 
effectively and limiting iatrogenic disease associated with medication. 
 
Please insert table 1 here. 
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There has been relatively little research on the impact of dementia on the 
prevalence of adverse drug events, in terms of adverse drug reactions (ADRs) 
and/or medication errors (Maidment et al, 2008; Gomez-Pavon et al, 2010). 
Dementia has, however, been identified as the main disease state which 
increases the likelihood that other risk factors for ADRs, including 
inappropriate prescribing, old age, adherence issues, drug interactions, 
comorbidity and polypharmacy, are present (Gomez-Pavon et al, 2010).  
 
Medication errors (any incident where there has been an error in the process 
of prescribing, dispensing, preparing, administering, monitoring or providing 
medicines advice, regardless of whether any harm occurred; NPSA, 2009) 
may also be more common in people with dementia due to the involvement of 
multiple health and social care professionals (Maidment et al, 2008). The 
direct impact of cognitive impairment is of course also important (Nirodi et al, 
2002). Within the general population, patients identify and thereby avoid 
nearly a quarter of errors, but both dementia and medication impair cognition 
and decision-making facilities (Boustani et al, 2003; Warner et al, 2005; 
Schubert et al, 2006; Maidment et al, 2008). Patients with dementia may be 
less likely to question a prescription or a change in medicine, be less aware of 
potential adverse events, and of whether monitoring is required, and therefore 
more likely to fail to identify a potential error (Maidment et al, 2006; Barber et 
al, 2009).  
 
Both adverse drug reactions and medication errors may lead to admission to 
resource-intensive care facilities. One of the largest studies of its type 
estimated that adverse drug events caused 6.5% of all admissions to 
secondary care facilities (Pirmohamed et al, 2004). The same study found 
that such events might account for as many as 6,000 deaths each year in 
England. In a study of 13,000 unplanned admissions, of which 714 (5.6%) 
were related to medication, impaired cognition was identified as the main 
predictor of preventable medication-related admission to hospital (Odds ratio, 
11.9; 95% confidence interval, 3.9 to 36.3; Leendertse et al, 2008).  
 
The impact of adverse drug events on admission to residential care facilities is 
less well studied. However, it is clear that people with dementia are frequently 
prescribed medicines with both anti-cholinergic and sedative activity, both of 
which impair cognition (Boustani et al, 2003; Mulsant et al, 2003). It has been 
estimated that 20 to 50% of people with dementia take at least one 
medication with anticholinergic activity (Boustani et al, 2003; Schubert et al, 
2006). Admission to residential care facilities is linked with impaired cognition 
and central ADRs could be associated with admission to residential care 
facilities via their impact on cognition.  
 
Informal carers of older people, such as family members, may conduct as 
many as 10 activities in relation to medication management, such as noticing 
and managing side-effects, deciding when to administer the medication and 
supplying appropriate information (Smith et al, 2003; Francis et al, 2002). 
They have a key role in ensuring safe medication management (Smith et al, 
2003; Francis et al, 2002). People with dementia often rely upon informal 
carers to manage their medication particularly as the dementia progresses 
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(Cotrell et al, 2006; Arlt et al, 2008). This role places significant strain on such 
carers (Francis et al, 2002). The greater the number of medication 
management related activities, the worse the social functioning and the 
mental health of the carer (Francis et al, 2002). People with dementia may 
over-estimate their ability to manage their own medication safely and there is 
a lack of research on both the causes, and the impact, of switching from self-
administration to carer-led administration (Cotrell et al, 2006; Arlt et al, 2008). 
One study, however, found that cognitive impairment was only associated 
with a difficulty in self-medicating safely in people prescribed complex 
medication regimens (Maddigan et al, 2003). 
 
Adherence to, and concordance with, prescribed medication may be 
particularly problematic for people with dementia (Mackin et al, 2007). An 
inability to manage complex medication regimens is a predictor for admission 
to residential care facilities (Lieto et al, 2005). A successful self-medication 
programme that includes adequate support, teaching the older person about 
the medication and other measures to improve compliance, can reduce the 
risk of medication errors and help maintain independence (Maddigan et al, 
2003). However, simply improving adherence may be counter-productive and 
an over-emphasis on adherence may increase the incidence of medication 
related iatrogenic disease (Holland et al, 2005; Holmes et al, 2006). In the 
HOMER trial - an intervention designed to improve medication management - 
a pharmacist-led, home-based medication review actually increased 
readmission rates in the intervention group compared to treatment as usual 
(234 vs. 178; OR 1.30, 95% confidence interval 1.07 to 1.58; P = 0.009) -  
possibly by over-encouraging improved adherence and thereby precipitating 
iatrogenic disease (Holland et al, 2005). Other trials of pharmacist-led 
medication review have produced variable results; though some studies have 
reduced the number of medicines prescribed, improving real life outcomes 
has been problematic (Zermansky et al, 2001; MEDMAN Team, 2007; 
Patterson et al, 2010; RESPECT Trial Team, 2010). 
 
Research to date in this area has tended to focus on the use of anti-
psychotics to treat behaviour that challenges. Such behaviour is amongst the 
main drivers for admission to residential care facilities (Holmes et al, 1998; 
Souetre et al, 1999; Gaugler et al, 2009; Ballard et al, 2010). Concern about 
the use of anti-psychotics in dementia has been highlighted for a long time 
(DoH, 2001). Recently the National Dementia Strategy targeted a two-thirds 
reduction in the use of anti-psychotics to treat behaviour that challenges 
(DoH, 2009b & 2010). While a significant proportion of anti-psychotic 
prescribing (in particular for long-term use) is inappropriate, this is an 
ambitious target and may prove unrealistic. The US 1987 Omnibus Budget 
Reconciliation Act (OBRA) restricted the use of anti-psychotics to certain 
approved indications, but only achieved a reduction in antipsychotic use of 
between 28 and 36% (Furniss, 2002; National Long Term Care Ombudsman 
Resource Center, 2011). Pharmacological methods will still be needed to treat 
acute behaviour that challenges; such a rigid and ambitious target may have 
adverse consequences such as the use of alternative unlicensed therapies for 
example, benzodiazepines, which are themselves are associated with serious 
side-effects (Ancill et al, 1991; Guthrie et al, 2010). Indeed, one large study 
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involving 4850 nursing home residents, which examined the impact of the 
OBRA guidelines, noted a 48.6% increase in regular and a 27.5% increase in 
‘as required’ prescriptions for anxiolytics such as benzodiazepines and 
buspirone (Borson et al, 1997).  
 
We conclude that medication management in dementia is a broad concept 
that should encompass a complete review of medication including 
assessment of indication, dosage, interactions and continued need. 
Optimising the management of all medication in dementia offers significant 
potential to improve dementia care in several ways:  
 
(a) improving the quality of care for people with dementia and their carers; 
(b) improving key outcomes, in dementia by reducing iatrogenic disease;  
(c) enhancing the healthcare professional/patient relationship, by for example 
empowering people with dementia and their carers;  
(d) reducing inappropriate medication and the need for resource intensive 
interventions consequent to mismanagement;  
(e) enhancing non-medication management pathways for people with 
dementia.  
 
Research is urgently needed to identify the most effective ways of delivering 
effective medication management in dementia.  
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Table 1 – Key Factors in Medication Management in Dementia 
 
Ensuring effective evidence-based treatments are utilised. 
Limiting adverse events associated with medication, such as adverse 
reactions and medication errors. 
Ensuring appropriate adherence to medication. 
Supporting the role of carers in safe and effective medication management. 
Ensuring that medication can facilitate independent living. 
 
